Company / Accounts Receivable
ResMed Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$939.5M
FY2025
5-year range
$576.0M / $939.5M
FY2021-FY2025
Trend
+12.2%
vs FY2024
Sector context
#28 of 143
Health Care
What the data says
ResMed's accounts receivable of $939M is higher than 80% of companies in the Health Care sector (FY2025). Accounts Receivable has increased for 3 consecutive years, from $576M in FY2022 to $939M in FY2025.
Based on SEC 10-K filings.
$939M in FY2025 with a 5-year CAGR of +14.6%. Top quartile in the Health Care sector.
Improved from $705M to $939M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +17.7%
- 5-Year CAGR
- +14.6%
- 10-Year CAGR
- -
Sector benchmark
-29.4% below sector average
Key checks
Key Insights
- ResMed's accounts receivable has grown for 3 consecutive years.
- 5-year CAGR of +14.6%, indicating consistent growth.
- In FY2025, accounts receivable increased 12.2% year-over-year.
- Ranks #28 out of 143 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- Strong profit margin: 27.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $939.5M | +12.2% |
| FY2024 | $837.3M | +18.8% |
| FY2023 | $704.9M | +22.4% |
| FY2022 | $576.0M | -6.2% |
| FY2021 | $614.3M | +29.4% |
| FY2020 | $474.6M | -10.2% |
| FY2019 | $528.5M | +9.3% |
| FY2018 | $483.7M | +7.4% |
| FY2017 | $450.5M | +17.9% |
| FY2016 | $382.1M | +5.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026